Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 14, 2017. The document serves as a transaction notification regarding a specific share acquisition by a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It details a single transaction involving the acquisition of Ordinary Shares.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882)
- Transaction Price: £16.2649 per share
- Transaction Volume: 34.944 shares
- Transaction Date: July 13, 2017
- Exchange: London Stock Exchange (XLON)
Material Changes
The filing does not provide comparative financial data or material changes to the company's overall financial position versus prior periods. The only reported activity is the acquisition of shares by Ms. C Thomas (SVP, HR) following the re-investment of dividends paid on July 13, 2017, on released shares from the Company's 2009 Deferred Annual Bonus Plan on a post-tax basis, including co-investment shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items beyond the specific transaction notification required by regulatory rules.
Investor Verification Points
- Verify the identity of the PDMR (Ms. C Thomas) and her role as SVP, HR.
- Confirm the transaction was executed on the London Stock Exchange on July 13, 2017.
- Note that the share acquisition resulted from dividend re-investment under the 2009 Deferred Annual Bonus Plan.
- Recognize that this filing does not contain financial performance data for the company.